Status:
COMPLETED
Bimatoprost Monotherapy vs. Dual Therapy With Travoprost and Timolol in Patients With Glaucoma and Ocular Hypertension
Lead Sponsor:
Innovative Medical
Conditions:
Glaucoma
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Evaluate the IOP-lowering efficacy and quality of life in patients using bimatoprost 0.03% monotherapy versus dual therapy with travoprost 0.004% and timolol 0.5% for the treatment of glaucoma or ocul...
Eligibility Criteria
Inclusion
- · Male or female \> 18 years of age
- Diagnosis of primary open-angle glaucoma or ocular hypertension
- Untreated IOP \> 18 mm Hg in each eye at the baseline evaluation
- Ability to provide informed consent and likely to complete all study visits
Exclusion
- · Known contraindication to bimatoprost, travoprost, timolol, or any component of any study medication
- Uncontrolled systemic disease
- Active ocular disease other than POAG or ocular hypertension
- Required use of ocular medications other than the study medications during the study (intermittent use of OTC artificial tear products will be permitted)
- History of intraocular surgery within the last 3 months
- Patient must not have discontinued use of any medication included in this study in the past for reasons of efficacy or intolerance
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00348023
Last Update
February 9 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dr. Noecker
Pittsburgh, Pennsylvania, United States, 15213